Vedran Pavlovic
0000-0002-9475-7201
Roche Products Ltd
7 papers found
Refreshing results…
Genetic variation in FCER1A predicts peginterferon alfa‐2a‐induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B
Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study
A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B
Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B
Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children with Chronic Hepatitis B: The PEG-B-ACTIVE Study
Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data
Long-Term Growth Outcomes in Children Treated for Chronic Hepatitis C
Missing publications? Search for publications with a matching author name.